One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Cingulate Inc.
CING · NCM · Healthcare · Biotechnology
Current price
$4.56
52-week range
$3.16 - $11.89
Market cap
$66.31M
Balance sheet
Healthy
-14.65x Concerning
Net cash $22.11M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Cingulate Inc.
Cingulate Inc. is developing new medicines to help people with ADHD and anxiety. Their main focus is on a new drug called CTx-1301, which is for ADHD and is currently in the final stage of testing before it can be approved. This matters because successful drug development could lead to significant future sales if the drugs are approved and widely used.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-4.02M
FY2024 Q4
$-4.28M
FY2025 Q2
$-4.80M
FY2025 Q3
$-4.24M
FY2025 Q4
$-3.75M
FY2026 Q1
$-6.97M
FY2026 Q2
$-5.97M
Revenue
—
Net income
$-5.87M
Diluted EPS
-0.45
Operating cash flow
$-5.90M
Free cash flow
$-5.97M
Fetching…
Sources
Revenue
—
Net income
$-9.31M
Diluted EPS
-0.95
Operating cash flow
$-6.91M
Free cash flow
$-6.97M
Fetching…
Sources
Revenue
—
Net income
$-6.52M
Diluted EPS
-0.96
Operating cash flow
$-3.60M
Free cash flow
$-3.75M
Fetching…
Sources
Revenue
—
Net income
$-7.34M
Diluted EPS
-1.35
Operating cash flow
$-4.24M
Free cash flow
$-4.24M
Fetching…
Sources
Revenue
—
Net income
$-4.79M
Diluted EPS
-1.09
Operating cash flow
$-4.80M
Free cash flow
$-4.80M
Fetching…
Sources
Revenue
—
Net income
$-3.80M
Diluted EPS
-1.04
Operating cash flow
$-4.61M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-6.13M
Diluted EPS
-2.30
Operating cash flow
$-4.08M
Free cash flow
$-4.28M
Fetching…
Sources
Revenue
—
Net income
$-3.23M
Diluted EPS
-1.83
Operating cash flow
$-3.88M
Free cash flow
$-4.02M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $4.56
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $22.1M - more cash than debt. Interest coverage -14.6x.
Net debt
$-22.11M
Interest coverage
-14.65x
Cingulate Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
CING
BASELINE
Cingulate Inc.
Total debt $6.29M Interest coverage -14.65x This is the baseline the peer rows are being compared against.
Total debt $7.40M Interest coverage -1,185.00x Neither company has much profit cushion over interest right now.
Total debt $1.67M Interest coverage -88.21x Neither company has much profit cushion over interest right now.
Total debt $1.18M Interest coverage -114.92x Neither company has much profit cushion over interest right now.
What you should know
The case for and against CING
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -198.7% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-5.18x
P/B
2.70x
P/S
—
EV/EBITDA
-1.81x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-198.7%
ROA
-66.9%
Health
Liquidity and balance-sheet strength
Debt / equity
0.27x
Current ratio
3.50x
Quick ratio
3.30x
Total debt
$6.29M
Total cash
$28.40M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-3.51
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-20.65M
Free CF TTM
$-17.41M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—